RxDoctor Payments Data

Colleen Johnson

Family · Rochester, NYNPI 1942471164

Payments from drug & device makers

$2,537in general payments, 2019–2025

Across 200 payments — averaging $12.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$751
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$734
  • Johnson & Johnson$204
  • Ironwood Pharmaceuticals, Inc$119
  • Takeda Pharmaceuticals U.S.A., Inc.$108
  • Bristol Myers Squibb$97
  • plus $524 from 14 others

What the payments were for

  • Food & beverage$2,537100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,537 in reported general payments places this provider in the 85th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$21,734
Medicare patients
165
Services billed
252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab34$318,261
StelaraUstekinumab11$283,063
LinzessLinaclotide81$80,835
ZenpepLipase/Protease/Amylase14$45,241
Mesalamine36$30,514
CreonLipase/Protease/Amylase12$13,303
TrulancePlecanatide21$11,768
Dexlansoprazole DrDexlansoprazole21$10,700
MovantikNaloxegol Oxalate18$9,736
Mesalamine DrMesalamine20$7,873
Pantoprazole Sodium505$7,219
SutabSod Sulf/Pot Chloride/Mag Sulf44$6,769
Omeprazole421$5,839
Colestipol Hcl34$5,489
Ursodiol41$5,446

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$204$283,06311 claims
AbbVieLinzess, Creon$751$94,13893 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$734$11,76821 claims
Braintree Laboratories, Inc.Sutab$22$6,76944 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,883 family providers in New York.

Other family in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →